Mesoblast (NASDAQ:MESO) Upgraded by StockNews.com to Hold

StockNews.com upgraded shares of Mesoblast (NASDAQ:MESO) from a sell rating to a hold rating in a research note issued to investors on Tuesday morning.

Separately, Cantor Fitzgerald restated an overweight rating on shares of Mesoblast in a research report on Friday, January 12th. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of Hold and an average price target of $13.67.

Mesoblast Stock Up 2.9 %

NASDAQ:MESO opened at $7.50 on Tuesday. The stock’s fifty day simple moving average is $4.30 and its 200-day simple moving average is $2.90. The firm has a market capitalization of $856.34 million, a P/E ratio of -6.70 and a beta of 3.45. Mesoblast has a 12-month low of $1.61 and a 12-month high of $10.24.

Institutional Trading of Mesoblast

A number of large investors have recently added to or reduced their stakes in the company. Lazari Capital Management Inc. increased its position in Mesoblast by 9.3% during the third quarter. Lazari Capital Management Inc. now owns 94,034 shares of the company’s stock worth $116,000 after buying an additional 8,000 shares during the last quarter. Chase Investment Counsel Corp acquired a new position in shares of Mesoblast during the 1st quarter worth approximately $298,000. Finally, Prosperity Wealth Management Inc. bought a new stake in Mesoblast in the 3rd quarter valued at $79,000. Institutional investors and hedge funds own 1.43% of the company’s stock.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.